Syngene concludes acquisition of biologics facility from Stelis Biopharma
The acquisition of the ‘Unit 3’ biologics manufacturing facility was concluded at a revised gross value of Rs 617 crores adjusted…
Recover your password.
A password will be e-mailed to you.